Eli Lilly said its eczema drug lebrikizumab (Ebglyss) showed durable long-term response in a late-stage study, with data highlighting sustained efficacy over an extended treatment duration.

The study findings showed that patients experienced persistent relief from itch for up to four years, indicating long-term symptom control in individuals undergoing treatment. The results are based on extended follow-up data from patients receiving lebrikizumab, demonstrating continued effectiveness across the study period.

Lebrikizumab is indicated for the treatment of moderate-to-severe atopic dermatitis (eczema), a chronic inflammatory skin condition. The therapy works by targeting the interleukin-13 (IL-13) pathway, a key cytokine involved in driving type-2 inflammation associated with atopic dermatitis.

The late-stage study evaluated the long-term impact of the therapy, focusing on sustained symptom relief and disease control. Patients maintained consistent clinical response over multiple years, reflecting the drug’s ability to provide prolonged therapeutic benefit.

The findings also showed that the treatment continued to deliver stable outcomes in itch reduction and overall disease management, which are key clinical endpoints in eczema therapy.

Lebrikizumab’s mechanism of action, targeting IL-13, supports its role in addressing the underlying inflammatory pathways of the disease, contributing to long-term disease control observed in the study.

The data reinforce lebrikizumab’s position as a treatment option for patients with moderate-to-severe eczema, with evidence supporting durable efficacy and sustained symptom improvement over extended periods of use.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!